Canada's Population Health Model (POHEM): A tool for performing economic evaluations of cancer control interventions

European Journal of Cancer

Volumn 37, Issue 14, 2001, Pages 1797-1804

  Will, B P ^a   Berthelot, J M ^a   Nobrega, K M ^a   Flanagan, W ^a   Evans, W K ^b  

^a STATISTICS CANADA   (Canada)

^b CANCER CARE ONTARIO   (Canada)

Author keywords

Cancer control; Economic evaluation; Microsimulation model

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; TAMOXIFEN; VINBLASTINE; VINDESINE;

ARTICLE; BREAST CANCER; CANADA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RISK; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE POLICY; HIGH RISK POPULATION; HOME CARE; HOSPITALIZATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANADA; CARCINOMA, NON-SMALL-CELL LUNG; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; LUNG NEOPLASMS; MODELS, ECONOMETRIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0034877422     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00204-0     Document Type: Article

References (26)

1. The cost of combined modality interventions for Stage III non-small cell lung cancer
2. The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in Stage IV non-small cell lung cancer
3. An estimate of the cost effectiveness of gemcitabine in Stage IV non-small cell lung cancer
4. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small cell lung cancer
5. An economic evaluation of screening and treatment of pre-clinical lung cancer
6. Should long-term hormone replacement therapy in postmenopausal women be promoted?
7. The economic impact of Locoregional Radiotherapy (LRRT) on all post-surgical stage II breast cancer patients in Canada
8. Modeling the impacts of colorectal cancer screening in Canada with POHEM
9. The use of POHEM in assessing the health impacts of earlier diagnosis of colorectal cancer in Canada
10. Decision framework for chemotherapeutic interventions for metastatic non-small cell lung cancer
11. Economic impact of introducing ambulatory breast conserving surgery (BCS) and a two-day in-hospital stay for mastectomy (M) for Canadian breast cancer patients
12. Breast cancer: Better care for less cost: Is it possible?
13. Economic and health impacts of administering preventive tamoxifen to women at high risk of breast cancer in Canada
14. Risk evaluation of the administration of preventive tamoxifen to a Canadian cohort of women
15. POHEM-A framework for understanding and modelling the health of human populations
16. Use of longitudinal data in health policy simulation models
17. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs
18. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model
19. Management of metastatic non-small cell lung cancer and a consideration of cost
20. A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada
21. Diagnostic and therapeutic approaches for non-metastatic breast cancer in Canada and their associated costs
22. Estimates of the lifetime costs of breast cancer treatment in Canada
23. Estimating the cost of coronary heart disease in Manitoba
24. Theoretical foundations of cost-effectiveness analysis
25. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
26. Weighing the risks and benefits of tamoxifen treatment for treating breast cancer